Self.co, a Vilnius-based digital well being firm serving to customers perceive and handle allergic reactions and meals intolerances, has raised €2.56 million in a mixed grant and enterprise funding spherical to help the enlargement into new markets and additional growth of Self.co’s proprietary testing know-how and long-term administration instruments.
The funding spherical of €1.2 million was led by Iron Wolf Capital, with participation from Coinvest, NGL Ventures, and a number of other angel buyers. Self.co acquired the €1.36 million grant from Innovation Company Lithuania to enhance its testing know-how.
Tautvydas Gylys, co-founder and CEO of Self.co, mentioned: “Hundreds of thousands of individuals dwell with allergy-like signs however and not using a actual understanding of what’s inflicting them or what to do about it. We’ve taken superior diagnostic know-how and constructed a easy check system that offers anybody clear, medically legitimate solutions with out the excessive price or lengthy wait.
This elevate for Self.co matches right into a broader European pattern of continued funding in diagnostics and digital well being throughout 2025.
EU-Startups protection exhibits a gentle circulate of comparable rounds – as an example, CGC Genomics (Switzerland) secured €1.7 million to scale its regulated GenAI platform for genomic evaluation, whereas Cytely (Sweden) raised €3 million to increase its smart-microscopy diagnostic instruments. In Germany, roclub obtained €10 million to advance AI-powered distant operations in medical know-how.
Collectively, these offers underline a transparent 2025 sample of buyers supporting digital and AI-enabled diagnostic platforms that cut back testing prices or improve analytical velocity.
Self.co’s mannequin – integrating molecular allergy testing with digital symptom administration – displays this shift in direction of accessible, data-driven care options.
Whereas most funding exercise stays concentrated in nations corresponding to Switzerland, Germany, and Sweden, Self.co provides Baltic illustration to this increasing European HealthTech panorama.
“Now the funding will assist us convey our product to new markets just like the UK, Eire, Austria, and Germany, and deepen ongoing collaboration with healthcare programs in Poland and Lithuania,” added Gylys.
Based in 2015 by Gintautas Gylys, Self.co is a digital well being and diagnostics firm serving to individuals perceive allergy-like signs by way of molecular testing and knowledgeable steering.
The corporate controls its whole testing course of, from know-how growth to lab evaluation. Its proprietary microarray exams analyse 98 allergens and 220 meals sensitivities from a easy blood pattern taken at house or in companion clinics.
Past testing, Self.co gives customers with personalised avoidance plans and, when wanted, dietary supplements or remedies, empowering 1000’s to correctly diagnose allergy-like signs and dwell more healthy lives.
Kasparas Jurgelionis, Managing Associate at Iron Wolf Capital, says: “As DeepTech buyers, we again applied sciences with the potential to rework established industries – and that’s precisely what Self.co is doing in allergy diagnostics and care. It is a massive, fast-growing market nonetheless underserved by present options.”
Allergy symptoms and intolerances have an effect on between 30 and 40 % of the worldwide inhabitants, a quantity anticipated to climb to almost 4 billion individuals by mid-century (European Academy of Allergy and Clinical Immunology). Regardless of this prevalence, the corporate argues that analysis stays one in every of healthcare’s largest blind spots.
Round 45% of people with allergy-like signs within the EU are both misdiagnosed or by no means identified in any respect (EAACI). Many of those individuals confuse allergic reactions with different immune or digestive circumstances corresponding to intolerances or sensitivities, resulting in years of uncertainty and ineffective therapy.
The issue is compounded by lengthy ready occasions, usually greater than six months for specialist testing in public programs, and prohibitive prices. Layers of intermediaries, low check throughput, and supplier prices reportedly create markups on a single molecular allergy check of between €200 and €400. This places correct diagnoses prohibitively out of attain for hundreds of thousands.
Because of this, individuals proceed to dwell with fatigue, pores and skin rashes, or digestive signs with out actual solutions, whereas healthcare programs take up billions in avoidable prices every year.
Self.co’s digital service seems to deal with this with a holistic and scientific strategy. Its core merchandise are two proprietary microarray exams that analyse 98 allergens and 220 meals sensitivities utilizing a easy blood pattern that individuals can take at house or in a companion clinic.
As soon as evaluated by skilled lab technicians, Self.co gives customers with an in depth avoidance plan and connects them with dietary supplements and coverings as wanted by way of partnerships with native healthcare suppliers.
By controlling the whole testing course of, from know-how growth to lab evaluation, and eliminating intermediaries, Self.co provides the identical laboratory-grade testing for €69–€99, a fraction of the normal €200–€400 price.
“Tautvydas and the crew mix distinctive trade perception with robust execution, giving them a uncommon founder-market match. Self.co’s platform addresses long-standing ache factors for sufferers and clinicians, positioning the corporate to redefine allergy care globally. We’re proud to steer this spherical and help their mission to ship significant healthcare innovation at scale,” provides Jurgelionis.
Self.co’s testing know-how, developed by allergists and lab specialists, claims to attain molecular-level precision by way of microarray innovation. Superior calibration strategies tailor measurements for every allergen, reportedly guaranteeing accuracy even at very low ranges, whereas delicate fluorescence detection identifies the smallest immune responses. AI then merges medical knowledge and knowledgeable assessment to ship a personalised, actionable report.
Self.co will use the brand new funding to develop a complete digital well being platform that serves as an entry level for individuals experiencing allergy-like signs. The platform will embrace superior symptom questionnaires to pinpoint circumstances, expanded check choices, and higher integration with conventional healthcare programs.
Self.co says they’re aiming to turn into the go-to digital well being platform for top-to-bottom allergy care in Europe by 2030.
